52703-80-7

Basic information

• Product Name: AZEPAN-1-YL-ACETIC ACID
• Synonyms: TIMTEC-BB SBB010389;RARECHEM AL BO 1120;AKOS BBS-00000321;AZEPAN-1-YL-ACETIC ACID;IFLAB-BB F1981-0007;CHEMBRDG-BB 4013117;azepan-1-ylacetic acid(SALTDATA: FREE);2-(azepan-1-yl)acetic acid hydrochloride
• CAS NO: 52703-80-7
• Molecular Formula: C8H15NO2
• Molecular Weight: 157.21
• Mol File: 52703-80-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 270.5°C at 760 mmHg
• Flash Point: 117.4°C
• Appearance: /
• Density: 1.066g/cm³
• Vapor Pressure: 0.00192mmHg at 25°C
• Refractive Index: 1.483
• CAS DataBase Reference: AZEPAN-1-YL-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: AZEPAN-1-YL-ACETIC ACID(52703-80-7)
• EPA Substance Registry System: AZEPAN-1-YL-ACETIC ACID(52703-80-7)

Safety Data

• Statements: 52
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 52703-80-7(Hazardous Substances Data)

Usage

General Description

AZEPAN-1-YL-ACETIC ACID, also known as azepane acetic acid, is a chemical compound with the formula C9H19NO2. It is a derivative of azepane, a saturated heterocyclic compound containing seven carbon atoms and one nitrogen atom in the ring. Azepane acetic acid is commonly used as a pharmaceutical intermediate and as a building block in organic synthesis. Its structure and properties make it useful in the development of various medications and in the production of other chemical compounds. However, it is important to handle this chemical with care, as it may pose health and safety risks when not properly managed.

InChI:InChI=1/C8H15NO2/c10-8(11)7-9-5-3-1-2-4-6-9/h1-7H2,(H,10,11)

Upstream product

• 99065-22-2 Methyl 1-hexahydroazepine-acetate 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.